Otezla Shows Promise in Treating Ulcerative Colitis Patients in Phase 2 Clinical Trial, Company Says

Otezla Shows Promise in Treating Ulcerative Colitis Patients in Phase 2 Clinical Trial, Company Says
Otezla (apremilast), developed by Celgene Corporation, showed promising results in a group of active ulcerative colitis (UC) patients in a Phase 2 clinical trial, the company recently announced. Participants in the randomized study included ulcerative colitis patients who had failed at least one conventional treatment but had not received any biological therapy. Otezla is an oral inhibitor of phosphodiesterase 4 (PDE4), an enzyme associated with ulcerative colitis. The therapy is thought to control the production of inflammatory agents, but the company has not determined how yet. Otezla is currently approved in the United States as a t
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *